ZA200106478B - Dopamine D1 receptor agonist compounds. - Google Patents
Dopamine D1 receptor agonist compounds. Download PDFInfo
- Publication number
- ZA200106478B ZA200106478B ZA200106478A ZA200106478A ZA200106478B ZA 200106478 B ZA200106478 B ZA 200106478B ZA 200106478 A ZA200106478 A ZA 200106478A ZA 200106478 A ZA200106478 A ZA 200106478A ZA 200106478 B ZA200106478 B ZA 200106478B
- Authority
- ZA
- South Africa
- Prior art keywords
- chloro
- solution
- dopamine
- tetrahydro
- benzazepine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 29
- 229940098305 Dopamine D1 receptor agonist Drugs 0.000 title description 3
- 239000000510 dopamine 1 receptor stimulating agent Substances 0.000 title description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 11
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960003638 dopamine Drugs 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 claims description 4
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 5
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- -1 1-thienyl Chemical group 0.000 description 4
- YTKGUKHQYUHYTQ-UHFFFAOYSA-N 2-(2-chloro-3,4-dimethoxyphenyl)ethanamine Chemical compound COC1=CC=C(CCN)C(Cl)=C1OC YTKGUKHQYUHYTQ-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 150000008038 benzoazepines Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- KRGCVMIDKXZOKL-UHFFFAOYSA-N 9-chloro-5-(2,3-dihydro-1h-inden-5-yl)-7,8-dimethoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C=1C=C2CCCC2=CC=1C1CN(C)CCC2=C1C=C(OC)C(OC)=C2Cl KRGCVMIDKXZOKL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CDBYDFFJDIKENV-UHFFFAOYSA-N 1-(1-benzofuran-7-yl)-2-[2-(2-chloro-3,4-dimethoxyphenyl)ethylamino]ethanol Chemical compound ClC1=C(OC)C(OC)=CC=C1CCNCC(O)C1=CC=CC2=C1OC=C2 CDBYDFFJDIKENV-UHFFFAOYSA-N 0.000 description 1
- GMXUVTDBTCMBDR-UHFFFAOYSA-N 1-(1-benzothiophen-5-yl)-2-[2-(2-chloro-3,4-dimethoxyphenyl)ethylamino]ethanol Chemical compound ClC1=C(OC)C(OC)=CC=C1CCNCC(O)C1=CC=C(SC=C2)C2=C1 GMXUVTDBTCMBDR-UHFFFAOYSA-N 0.000 description 1
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical class C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 description 1
- DERKIXIWEXOQDE-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)oxirane Chemical compound C1OC1C1=CC=C(SC=C2)C2=C1 DERKIXIWEXOQDE-UHFFFAOYSA-N 0.000 description 1
- WENHVAQVKYHFHW-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-5-yl)oxirane Chemical compound C1OC1C1=CC=C(CCC2)C2=C1 WENHVAQVKYHFHW-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LVTNBPWQCQPAKR-UHFFFAOYSA-N 5-(1-benzofuran-7-yl)-9-chloro-7,8-dimethoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C=1C=CC=2C=COC=2C=1C1CN(C)CCC2=C1C=C(OC)C(OC)=C2Cl LVTNBPWQCQPAKR-UHFFFAOYSA-N 0.000 description 1
- UEISFSKTAZATNE-UHFFFAOYSA-N 5-(1-benzothiophen-7-yl)-9-chloro-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C=1C=CC=2C=CSC=2C=1C1CNCCC2=C1C=C(OC)C(OC)=C2Cl UEISFSKTAZATNE-UHFFFAOYSA-N 0.000 description 1
- HPKXBMNENNYRHS-UHFFFAOYSA-N 5-(5,6,7,8-tetrahydronaphthalen-2-yl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol Chemical compound C1=2C=C(O)C(O)=CC=2CCNCC1C1=CC=C(CCCC2)C2=C1 HPKXBMNENNYRHS-UHFFFAOYSA-N 0.000 description 1
- NTQITNFCVDCQEC-UHFFFAOYSA-N 5-(furan-2-yl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical class C1NCCC2=CC=CC=C2C1C1=CC=CO1 NTQITNFCVDCQEC-UHFFFAOYSA-N 0.000 description 1
- ABVQLNWUASCTKR-UHFFFAOYSA-N 5-phenyl-3h-3-benzazepine Chemical class C=1NC=CC2=CC=CC=C2C=1C1=CC=CC=C1 ABVQLNWUASCTKR-UHFFFAOYSA-N 0.000 description 1
- ZNILXSHYEVKFAU-UHFFFAOYSA-N 7-(oxiran-2-yl)-1-benzofuran Chemical compound C1OC1C1=CC=CC2=C1OC=C2 ZNILXSHYEVKFAU-UHFFFAOYSA-N 0.000 description 1
- UUTNTBWYKFDEDO-UHFFFAOYSA-N 9-chloro-5-(2,3-dihydro-1h-inden-5-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol Chemical compound C=1C=C2CCCC2=CC=1C1CN(C)CCC2=C1C=C(O)C(O)=C2Cl UUTNTBWYKFDEDO-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PLSXYMFBBDITPN-UHFFFAOYSA-N C1N(C)CCC2=C(Cl)C(O)=C(O)C=C2C1C1=CC=C(SC=C2)C2=C1 Chemical compound C1N(C)CCC2=C(Cl)C(O)=C(O)C=C2C1C1=CC=C(SC=C2)C2=C1 PLSXYMFBBDITPN-UHFFFAOYSA-N 0.000 description 1
- 101150043532 CISH gene Proteins 0.000 description 1
- 102100034741 Cyclin-dependent kinase 20 Human genes 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 101500014379 Lymnaea stagnalis Ovulation hormone Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9903671.7A GB9903671D0 (en) | 1999-02-17 | 1999-02-17 | Dopamine D-1 receptor agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200106478B true ZA200106478B (en) | 2002-02-07 |
Family
ID=10847990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200106478A ZA200106478B (en) | 1999-02-17 | 2001-08-07 | Dopamine D1 receptor agonist compounds. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1157009A1 (zh) |
| JP (1) | JP2002537288A (zh) |
| KR (1) | KR20010108228A (zh) |
| CN (1) | CN1142916C (zh) |
| AU (1) | AU767332B2 (zh) |
| BR (1) | BR0008329A (zh) |
| CA (1) | CA2363695A1 (zh) |
| CZ (1) | CZ20012973A3 (zh) |
| EA (1) | EA004745B1 (zh) |
| GB (1) | GB9903671D0 (zh) |
| HU (1) | HUP0200057A3 (zh) |
| IL (1) | IL144810A0 (zh) |
| MX (1) | MXPA01008294A (zh) |
| NO (1) | NO20013978L (zh) |
| PL (1) | PL349838A1 (zh) |
| WO (1) | WO2000049000A1 (zh) |
| ZA (1) | ZA200106478B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130576D0 (en) * | 2001-12-20 | 2002-02-06 | Cenes Ltd | Dopamine D1 receptor agonist pro-drug compounds & derivatives |
| KR20080044840A (ko) | 2005-07-15 | 2008-05-21 | 에이엠알 테크놀로지, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도 |
| AU2006278514A1 (en) * | 2005-08-03 | 2007-02-15 | Mia Levite | Killing human lymphoma and leukemia cancer cells and TCR-activated normal human cells by dopamine D1R agonists |
| CN101684096A (zh) * | 2008-09-23 | 2010-03-31 | 中国科学院上海药物研究所 | 一类新型苯并氮杂卓类化合物及其制备方法和用途 |
| CN102276531A (zh) * | 2011-05-30 | 2011-12-14 | 扬子江药业集团广州海瑞药业有限公司 | 一种甲磺酸非诺多泮的制备方法 |
| CA2916653C (en) | 2013-06-27 | 2017-07-18 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1561305A (en) * | 1975-07-02 | 1980-02-20 | Smithkline Corp | Benzazepine derivatives and pharmeceutical compositions containing them |
| US4111957A (en) * | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| US4265889A (en) * | 1978-05-05 | 1981-05-05 | Smithkline Corporation | 6-Lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| US4707483A (en) * | 1985-12-20 | 1987-11-17 | Smithkline Beckman Corporation | 1-phenyl-3-benzazepines and their use for treating gastrointestinal motility disorders |
| US4861771A (en) * | 1989-01-27 | 1989-08-29 | Smithkline Beckman Corporation | Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as prodrugs |
-
1999
- 1999-02-17 GB GBGB9903671.7A patent/GB9903671D0/en not_active Ceased
-
2000
- 2000-02-17 IL IL14481000A patent/IL144810A0/xx unknown
- 2000-02-17 KR KR1020017010418A patent/KR20010108228A/ko not_active Application Discontinuation
- 2000-02-17 MX MXPA01008294A patent/MXPA01008294A/es unknown
- 2000-02-17 CZ CZ20012973A patent/CZ20012973A3/cs unknown
- 2000-02-17 BR BR0008329-1A patent/BR0008329A/pt not_active IP Right Cessation
- 2000-02-17 CN CNB00803947XA patent/CN1142916C/zh not_active Expired - Fee Related
- 2000-02-17 HU HU0200057A patent/HUP0200057A3/hu unknown
- 2000-02-17 JP JP2000599740A patent/JP2002537288A/ja active Pending
- 2000-02-17 EP EP00903881A patent/EP1157009A1/en not_active Withdrawn
- 2000-02-17 CA CA002363695A patent/CA2363695A1/en not_active Abandoned
- 2000-02-17 EA EA200100783A patent/EA004745B1/ru not_active IP Right Cessation
- 2000-02-17 PL PL00349838A patent/PL349838A1/xx not_active Application Discontinuation
- 2000-02-17 AU AU25632/00A patent/AU767332B2/en not_active Ceased
- 2000-02-17 WO PCT/GB2000/000570 patent/WO2000049000A1/en not_active Application Discontinuation
-
2001
- 2001-08-07 ZA ZA200106478A patent/ZA200106478B/en unknown
- 2001-08-15 NO NO20013978A patent/NO20013978L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2563200A (en) | 2000-09-04 |
| WO2000049000A1 (en) | 2000-08-24 |
| HUP0200057A2 (en) | 2002-08-28 |
| NO20013978D0 (no) | 2001-08-15 |
| CN1341102A (zh) | 2002-03-20 |
| NO20013978L (no) | 2001-08-15 |
| BR0008329A (pt) | 2002-01-29 |
| MXPA01008294A (es) | 2002-07-02 |
| AU767332B2 (en) | 2003-11-06 |
| EP1157009A1 (en) | 2001-11-28 |
| KR20010108228A (ko) | 2001-12-07 |
| CN1142916C (zh) | 2004-03-24 |
| CZ20012973A3 (cs) | 2002-01-16 |
| GB9903671D0 (en) | 1999-04-14 |
| IL144810A0 (en) | 2002-06-30 |
| EA004745B1 (ru) | 2004-08-26 |
| HUP0200057A3 (en) | 2004-03-29 |
| PL349838A1 (en) | 2002-09-23 |
| CA2363695A1 (en) | 2000-08-24 |
| EA200100783A1 (ru) | 2002-02-28 |
| JP2002537288A (ja) | 2002-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI95246C (fi) | Menetelmä terapeuttisesti käyttökelpoisten, substituoitujen aminometyylibentsodihydropyraanien ja aminometyyli(di- ja tetra)hydronaftaleenien valmistamiseksi | |
| KR100361950B1 (ko) | 3-인돌릴피페리딘 | |
| EP1337528B1 (en) | Benzothiophene derivative compounds, process of preparation and use thereof | |
| JP2001515485A (ja) | ジオキシノ誘導体および治療薬としてのその使用 | |
| FI95464B (fi) | Menetelmä terapeuttisesti käyttökelpoisen 4-(di-n-propyyli)amino-6-aminokarbonyyli-1,3,4,5-tetrahydrobentso/c,d/indolihippuraatin valmistam iseksi | |
| WO2006103559A1 (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
| CA2157668C (en) | Tricyclic 2,3,4,5-tetrahydro-1h-3-benzazepines, their use and preparation | |
| AU767332B2 (en) | Dopamine D1 receptor agonist compounds | |
| JP7390401B2 (ja) | 縮合環化合物、その製造方法及び用途 | |
| AU714711B2 (en) | Galanthamine derivatives and process for their preparation | |
| CA2179205A1 (en) | Benzisothiazolyl-substituted aminomethylchromans | |
| SK361292A3 (en) | Piperidylmethyl-substituted chroman derivatives, process for producing them, their use and pharmaceutical composition containg same | |
| AU9751798A (en) | Aminomethyl-benzo{a}quinolizidine derivatives, preparation and therapeutic applications for neurodegenrative diseases | |
| EP2133350B1 (en) | A method for the preparation of an enantiomerically pure benzazepine | |
| PL168815B1 (pl) | Sposób wytwarzania pochodnych N-2-chlorobenzylo-2-okso i N-2-chlorobenzylo-2,2-diokso-1,2,3-oksatiazolidyny PL PL PL | |
| US20080255349A1 (en) | Method for the preparation of an enantiomerically pure benzazepine | |
| WO2003053936A1 (en) | Dopamine d1 receptor agonist pro-drug compounds & derivatives | |
| AU1393100A (en) | Novel 3-alkoxybenzylamine derivatives and their use as medicines for treating schizophrenia | |
| MXPA01006854A (es) | 3,4-dihidro-2h- benzo[1,4]oxazinil -metil [3-(1h-indol-3il) -alquil]-aminas |